Vitenskapelig artikkel

• Anne Hansen Ree; Paula A. Bousquet; Tina Visnovska et al. (2026). Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. (ekstern lenke)
• Rachel P. Riechelmann; Giovana T. Torrezan; Emily Bergsland et al. (2025). Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. (ekstern lenke)
• Gitte Dam; Henning Grønbæk; Halfdan Sorbye et al. (2020). Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. (ekstern lenke)
• Rocio Garcia-Carbonero; Anja Rinke; Juan W Valle et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. (ekstern lenke)
• Andreas Venizelos; Hege Elvebakken; Aurel Perren et al. (2021). The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Erik Tanis; Catherine Julié; Jean-Francois Emile et al. (2015). Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. (ekstern lenke)
• Stine Brændegaard Winther; Gabor Isivan Liposits; Halla Skuladottir et al. (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. (ekstern lenke)
• Philip Falk; Mira Severin; Åke Berglund et al. (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. (ekstern lenke)
• Dimitrios Papantoniou; Malin Grönberg; Espen Thiis-Evensen et al. (2023). Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. (ekstern lenke)
• Halfdan Sørbye; P Pfeiffer; N Cavalli-Bjorkman et al. (2009). Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. (ekstern lenke)
• Halfdan Sorbye; Anca Dragomir; Magnus Sundström et al. (2015). High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. (ekstern lenke)
• Julian Hamfjord; Tormod Kyrre Guren; Olav Dajani et al. (2019). Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. (ekstern lenke)
• Staffan Welin; Halfdan Sørbye; Sigrunn Sebjørnsen et al. (2011). Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. (ekstern lenke)
• Maria Thomsen; Marianne Guren; Eva Skovlund et al. (2017). Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. (ekstern lenke)
• Line Schmidt Tarpgaard; Tormod Kyrre Guren; Bengt Glimelius et al. (2014). Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. (ekstern lenke)
• Halfdan Sorbye; Murielle Mauer; Thomas Gruenberger et al. (2012). Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). (ekstern lenke)
• Line Schmidt Tarpgaard; Maj Sofie Ørum-Madsen; Ib Jarle Christensen et al. (2016). TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. (ekstern lenke)
• Arvind Dasari; Kathan Mehta; Lauren Averett Byers et al. (2018). Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. (ekstern lenke)
• Emerik Osterlund; Ari Ristimäki; Soili Kytölä et al. (2022). KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer. (ekstern lenke)
• Abir Salwa Ali; Malin Grönberg; Birgitte Federspiel et al. (2017). Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. (ekstern lenke)
• Abir Salwa Ali; Aurel Perren; Cecilia Lindskog et al. (2020). Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. (ekstern lenke)
• Halfdan Sørbye; Bengt Glimelius; Å Berglund et al. (2004). Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. (ekstern lenke)
• Arvind Dasari; Chan Shen; Anjali Devabhaktuni et al. (2022). Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. (ekstern lenke)
• Nils Hovdenak; Halfdan Sørbye; Olav Dahl (2005). SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. (ekstern lenke)
• Martin Fassnacht; Massimo Terzolo; Bruno Allolio et al. (2012). Combination Chemotherapy in Advanced Adrenocortical Carcinoma. (ekstern lenke)
• Janne Beathe Kjersem; Tone Ikdahl Andersen; Tormod Kyrre Guren et al. (2012). Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. (ekstern lenke)
• Emerik Osterlund; Ari Ristimäki; Markus J. Mäkinen et al. (2023). Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. (ekstern lenke)
• Halfdan Sorbye; Eric Baudin; Ivan Borbath et al. (2019). Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (ekstern lenke)
• Line Schmidt Tarpgaard; Ib J. Christensen; Gunilla Høyer-Hansen et al. (2015). Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. (ekstern lenke)
• Per Pfeiffer; Halfdan Sorbye; Camilla Qvortrup et al. (2015). Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. (ekstern lenke)
• Erik Tanis; Bernard Nordlinger; Murielle Mauer et al. (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. (ekstern lenke)
• Halfdan Sørbye; Øystein Bruserud; Olav Dahl (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. (ekstern lenke)
• Bengt Glimelius; Halfdan Sørbye; L Balteskard et al. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. (ekstern lenke)
• Halfdan Sørbye; Dag Jensen; Olav Dahl (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. (ekstern lenke)
• Halfdan Sorbye; Geir Olav Hjortland; L.W. Vestermark et al. (2024). NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Synne Wollen Steen; Halfdan Sorbye; Mehran Jazbani et al. (2023). Takotsubosyndrom under behandling med fluorouracil. (ekstern lenke)
• Håvard Trønnes; Hans Kristian Haugland; Albert N. Bekassy et al. (2012). Small Cell Lung Cancer in a 14-Year-Old Girl. (ekstern lenke)
• Stine Brændegaard Winther; Pia Österlund; Åke Berglund et al. (2017). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. (ekstern lenke)
• Stein Gunnar Larsen; Mariusz Adam Goscinski; Svein Dueland et al. (2021). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. (ekstern lenke)
• Laurids Ø. Poulsen; Camilla Qvortrup; Per Pfeiffer et al. (2015). Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much?. (ekstern lenke)
• Julian Hamfjord; Tormod Kyrre Guren; Bengt Glimelius et al. (2021). Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. (ekstern lenke)
• Kjell Kåre Øvrebø; Asbjørn Svardal; Stener Kvinnsland et al. (1999). Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. (ekstern lenke)
• Kjell Kåre Øvrebø; Halfdan Sørbye; Asbjørn Svardal et al. (1997). Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. (ekstern lenke)
• Kristine Øverås Aasebø; Jarle Bruun; Christian Holst Bergsland et al. (2022). Prognostic role of tumour infiltrating lymphocytes and macrophages in relation to tumour MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. (ekstern lenke)
• Halfdan Sørbye; Olav Dahl (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. (ekstern lenke)
• Artur Mezheyeuski; Fredrik Pontén; Per-Henrik Edqvist et al. (2019). Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. (ekstern lenke)
• Gudrun Maria Waaler Bjørnelv; Svein Dueland; Pål Dag Line et al. (2018). Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.. (ekstern lenke)
• Stian Knappskog; Tobias Grob; Andreas Venizelos et al. (2023). Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma. (ekstern lenke)
• Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius et al. (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (ekstern lenke)
• Halfdan Sørbye (2008). Prognostic clinical factors in metastatic colorectal cancer. (ekstern lenke)
• Tormod Kyrre Guren; Maria Thomsen; Elin H. Kure et al. (2017). Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. (ekstern lenke)
• Hege Elvebakken; Geir Olav Hjortland; Herish Garresori et al. (2023). Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Pål Joranger; Arild Nesbakken; Geir Hoff et al. (2015). Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. (ekstern lenke)
• Jon-Helge Angelsen; Arild Horn; Halfdan Sorbye et al. (2017). Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. (ekstern lenke)
• Pål Joranger; Arild Nesbakken; Halfdan Sorbye et al. (2019). Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. (ekstern lenke)
• Siren Morken; Seppo W. Langer; Anna Sundlöv et al. (2023). Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Nina Cavalli-Björkman; Camilla Qvortrup; Sigrunn Sebjørnsen et al. (2012). Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. (ekstern lenke)
• Sampsa Kinos; Helga Hagman; Päivi Halonen et al. (2024). Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study). (ekstern lenke)
• Magne Kjell Tveit; Tormod Kyrre Guren; Bengt Glimelius et al. (2012). Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. (ekstern lenke)
• Halfdan Sorbye; Milada Cvancarova Småstuen; Camilla Qvortrup et al. (2013). Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. (ekstern lenke)
• Hege Elvebakken; Aurel Perren; Jean-Yves Scoazec et al. (2020). A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. (ekstern lenke)
• Luís Nunes; Kristine Aasebø; Lucy Mathot et al. (2020). Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. (ekstern lenke)
• Kristine Aasebø; Anca Dragomir; Magnus Sundström et al. (2020). CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. (ekstern lenke)
• Anita Sveen; Inger Marie Løes; Sharmini Alagaratnam et al. (2016). Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. (ekstern lenke)
• Kjell Kåre Øvrebø; Halfdan Sørbye; Stener Kvinnsland et al. (1998). Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. (ekstern lenke)
• Nils Hovdenak; Åsa Karlsdottir; Halfdan Sørbye et al. (2003). Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. (ekstern lenke)
• Kjell Kåre Øvrebø; Knut Svanes; Steinar Torbjørn Aase et al. (2002). Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. (ekstern lenke)
• Elinor Margrethe Chelsom Vogt; Katrin Hammerling; Halfdan Sorbye et al. (2021). Feminizing adrenal tumor identified by plasma steroid profiling. (ekstern lenke)
• Pia Österlund; Halfdan Sorbye; Per Pfeiffer et al. (2016). Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. (ekstern lenke)
• Aurel A. Perren; Anne Couvelard; Jean-Yves Scoazec et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. (ekstern lenke)
• Ulrich Peter Knigge; Magnus Kjellman; Henning Grønbæk et al. (2025). Association rule mining of clinical and biomarker data in neuroendocrine tumors: A prospective study on disease progression. (ekstern lenke)
• Mairéad G. McNamara; Halfdan Sørbye; Nehara Begum et al. (2025). Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract. (ekstern lenke)
• Sebastian Meltzer; Anne Negård; Kine Mari Bakke et al. (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. (ekstern lenke)
• Halfdan Sørbye; Dag Jensen; Olav Dahl (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. (ekstern lenke)
• Artur Mezheyeuski; Maja Bradic Lindh; Tormod Kyrre Guren et al. (2016). Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. (ekstern lenke)
• B Nordlinger; T Gruenberger; Halfdan Sørbye et al. (2008). Surgery vs surgery and chemotherapy for colorectal liver metastases. (ekstern lenke)
• Julian Hamfjord; Tormod Kyrre Guren; Bengt Glimerius et al. (2024). Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer. (ekstern lenke)
• Maria Thomsen; Christian Kersten; Halfdan Sorbye et al. (2016). Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. (ekstern lenke)
• Jon-Helge Angelsen; Asgaut Viste; Inger Marie Løes et al. (2015). Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. (ekstern lenke)
• Kristine Aasebø; Anca Dragomir; Magnus Sundström et al. (2019). Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. (ekstern lenke)
• Anja Rinke; Christoph J. Auernhammer; Lisa Bodei et al. (2021). Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. (ekstern lenke)
• Rodney J. Hicks; Clarisse Dromain; Wouter De Herder et al. (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. (ekstern lenke)
• Inger Marie Løes; Heike Immervoll; Halfdan Sorbye et al. (2016). Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. (ekstern lenke)
• Halfdan Sorbye; Liv Sylvi Meyer; Kjerstin Elisabeth Skrede Mordal et al. (2020). Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. (ekstern lenke)
• Gabor Isivan Liposits; Jesper Ryg; Halla Skuladottir et al. (2022). Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study. (ekstern lenke)
• Espen Thiis-Evensen; Magnus Kjellman; Ulrich Knigge et al. (2022). Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. (ekstern lenke)
• Kaitlyn K.H. Goey; Halfdan Sorbye; Bengt Glimelius et al. (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (ekstern lenke)
• Henning Langen Stokmo; Mahmoud Aly; Inger Marie Bowitz Lothe et al. (2022). Volumetric parameters from [18F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Maria Thomsen; Eva Skovlund; Halfdan Sorbye et al. (2018). Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. (ekstern lenke)
• Eva Tiensuu Janson; Ulrich Knigge; Gitte Dam et al. (2021). Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Halfdan Sorbye; Staffan Welin; Seppo W. Langer et al. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. (ekstern lenke)
• Halfdan Sørbye; Olav Dahl (2003). Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. (ekstern lenke)
• Kjell Kåre Øvrebø; Knut Svanes; Steinar Aase et al. (2002). Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. (ekstern lenke)
• Halfdan Sorbye; Eric Baudin; Aurel Perren (2018). The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. (ekstern lenke)
• Andreas Venizelos; Halfdan Sorbye; Hege Elvebakken et al. (2023). Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Artur Mezheyeuski; Carina Strell; Ina Hrynchyk et al. (2017). Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. (ekstern lenke)
• Stein Gunnar Larsen; Mariusz Adam Goscinski; Svein Dueland et al. (2022). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. (ekstern lenke)
• Anne Hansen Ree; Jurate Saltyte Benth; Hanne Mari Hamre et al. (2024). First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial. (ekstern lenke)
• Hans-Christian Pommergaard; Kirstine Nielsen; Halfdan Sorbye et al. (2021). Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. (ekstern lenke)
• C Qvortrup; M Yilmaz; Dagfinn Øgreid et al. (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. (ekstern lenke)
• Gabor Liposits; Halla Skuladottir; Jesper Ryg et al. (2022). The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—The Randomized NORDIC9-Study. (ekstern lenke)
• Halfdan Sorbye; Enrique Grande; Marianne Pavel et al. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. (ekstern lenke)
• Halfdan Sorbye; Geir Olav Hjortland; Lene Weber Vestermark et al. (2025). Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. (ekstern lenke)
• Gabor Liposits; Stine B. Winther; Jesper Ryg et al. (2023). The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study. (ekstern lenke)
• Eva Tiensuu Janson; Halfdan Sorbye; Staffan Welin et al. (2014). Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Bernard Nordlinger; Halfdan Sørbye; Bengt Glimelius et al. (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. (ekstern lenke)
• Renate Berget Galleberg; Ulrich Peter Knigge; Eva M. Tiensuu Janson et al. (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. (ekstern lenke)
• Jan P. Dumanski; Chiara Rasi; Peyman Björklund et al. (2017). A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. (ekstern lenke)
• ET Janson; Halfdan Sørbye; S Welin et al. (2010). Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. (ekstern lenke)
• Gabor Liposits; Henrik Eshoj; Sören Möller et al. (2021). Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—the randomized NORDIC9-study. (ekstern lenke)
• Marianne Pavel; Juan W Valle; Barbro Eriksson et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. (ekstern lenke)
• Magnus Kjellman; Ulrich Knigge; Staffan Welin et al. (2020). A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors. (ekstern lenke)
• Anne Hansen Ree; Eirik Høye; Qin Ying Esbensen et al. (2024). Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. (ekstern lenke)
• Arunabha Roy; David Cunningham; Robert Hawkins et al. (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. (ekstern lenke)
• Bengt Glimelius; Hans Garmo; Åke Berglund et al. (2011). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. (ekstern lenke)
• Halfdan Sørbye; Kristian Guttu; Hjørtur Gislason et al. (1993). Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. (ekstern lenke)
• Knut Jørgen Labori; Kristoffer Lassen; Dag Hoem et al. (2017). Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. (ekstern lenke)
• Abir Salwa Ali; Seppo W. Langer; Birgitte Federspiel et al. (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. (ekstern lenke)
• Christina Siesing; Halfdan Sorbye; Anca Dragomir et al. (2017). High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. (ekstern lenke)
• Esben Andreas Carlsen; Nicola Fazio; Dan Granberg et al. (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. (ekstern lenke)
• S.B. Winther; P. Østerlund; Å Berglund et al. (2016). NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan). (ekstern lenke)
• Rocio Garcia-Carbonero; Halfdan Sorbye; Eric Baudin et al. (2016). ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. (ekstern lenke)
• Stine Brændegaard Winther; Kanita Zubcevic; Camilla Qvortrup et al. (2016). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. (ekstern lenke)
• Halfdan Sørbye; Olav Dahl (2003). Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. (ekstern lenke)
• Abir Salwa Ali; Malin Grönberg; Seppo Wang Langer et al. (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (ekstern lenke)
• Kjell Kåre Øvrebø; Steinar Aase; Ketil Grong et al. (2002). Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. (ekstern lenke)
• P. Osterlund; S. Kinos; P. Pfeiffer et al. (2022). Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. (ekstern lenke)
• Sven-Petter Haugvik; Eva Tiensuu Janson; Pia Osterlund et al. (2016). Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. (ekstern lenke)
• Hege Elvebakken; Andreas Venizelos; Aurel Perren et al. (2024). Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms. (ekstern lenke)

Konferanseabstrakt

• Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius et al. (2012). Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. (ekstern lenke)
• Halfdan Sorbye; Andreas Venizelos; Hege Elvebakken et al. (2021). Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• B Nordlinger; Halfdan Sørbye; M Debois et al. (2005). Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. (ekstern lenke)
• C Qvortrup; M Cvancarova; B. Glimelius et al. (2012). AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. (ekstern lenke)
• Halfdan Sorbye; Staffan Welin; Seppo W. Langer et al. (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. (ekstern lenke)
• Per Pfeiffer; Bengt Glimelius; Stine Brændegaard Winther et al. (2019). Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. (ekstern lenke)
• Stian Knappskog; Halfdan Sorbye; Tim Grob et al. (2022). Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients. (ekstern lenke)
• Julian Hamfjord; Tormod Kyrre Guren; Olav Dajani et al. (2018). Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. (ekstern lenke)
• K Svanes; Hjørtur Gislason; Jon Erik Grønbech et al. (1993). Role of blood flow in the healing of gastric mucosal lesions.. (ekstern lenke)
• Baddar Pervaiz Butt; Henning Langen Stokmo; Mona Elisabeth Rootwelt-Revheim et al. (2021). Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas. (ekstern lenke)
• Magne Kjell Tveit; Tormod Kyrre Guren; Bengt Glimelius et al. (2010). Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. (ekstern lenke)
• Halfdan Sorbye; Staffan Welin; Seppo Langer et al. (2013). Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). (ekstern lenke)
• Per Pfeiffer; Halfdan Sorbye; Camilla Qvortrup et al. (2012). Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. (ekstern lenke)
• T Gruenberger; Halfdan Sørbye; M Debois et al. (2006). Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. (ekstern lenke)
• Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius et al. (2012). EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. (ekstern lenke)
• Line Schmidt Tarpgaard; Tormod Kyrre Guren; Bengt Glimelius et al. (2012). Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Halfdan Sorbye; Grace Kong; Simona Grozinsky-Glasberg (2020). PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (ekstern lenke)
• Manfred P. Lutz; John R. Zalcberg; Rob Glynne-Jones et al. (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. (ekstern lenke)
• Halfdan Sorbye; Grace Kong; Simona Grozinsky-Glasberg et al. (2024). PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). (ekstern lenke)
• Halfdan Sorbye; Jonathan Strosberg; Eric Baudin et al. (2014). Gastroenteropancreatic high-grade neuroendocrine carcinoma. (ekstern lenke)
• Halfdan Sørbye; M Brændengen; L Balteskard (2008). Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. (ekstern lenke)
• Gitte Dam; Henning Grønbæk; Anna Sundlöv et al. (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. (ekstern lenke)
• Martin Biermann; Boel Johnsen; Halfdan Sørbye et al. (2009). Positronemisjonstomografi ved nevroendokrine svulster. (ekstern lenke)
• Nikolaos Andreatos; Patrick W. McGarrah; Mohamad Bassam Sonbol et al. (2023). Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. (ekstern lenke)
• Kaitlyn K.H. Goey; Remi Mahmoud; Halfdan Sorbye et al. (2018). Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. (ekstern lenke)

Vitenskapelig bokkapittel

• Ragnar Telhaug; Jan Erik Varhaug; Halfdan Sørbye et al. (2009). Endokrine svulster. (ekstern lenke)
• Halfdan Sørbye (2008). The use of Chemotherapy for Neuroendocrine Tumors. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Dag Hoem et al. (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. (ekstern lenke)
• RM Bremnes; P Endresen; Halfdan Sørbye (1999). Antimetabolitter. (ekstern lenke)
• Halfdan Sorbye (2014). Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. (ekstern lenke)

Leserbrev

• Halfdan Sorbye (2019). Ekspertpanel for ny vurdering ved alvorlig sykdom. (ekstern lenke)
• Halfdan Sorbye; Murielle Mauer; Bernard Nordlinger (2015). Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)". (ekstern lenke)

Rettelse i tidsskrift

• Manfred P. Lutz; John R. Zalcberg; Rob Glynne-Jones et al. (2016). Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). (ekstern lenke)
• Halfdan Sorbye; Geir Olav Hjortland; Lene Weber Vestermark et al. (2025). Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. (ekstern lenke)

Konferanseposter

• Anne Hansen Ree; Hanne Mari Hamre; Christian Kersten et al. (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study. (ekstern lenke)
• Halfdan Sørbye; Bengt Glimelius; Åke Berglund et al. (2003). Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer. (ekstern lenke)
• K Guttu; Halfdan Sorbye; K. Svanes et al. (1993). Effect of restricted hyperaemic response and systemic alkalinization on gastric luminal bicarbonate release and mucosal restitution after hyperomolar damage in the cat.. (ekstern lenke)
• Pål Joranger; Arild Nesbakken; Geir Hoff et al. (2014). Development and validation of a Norwegian model for colorectal cancer. (ekstern lenke)
• Sebastian Meltzer; Anne Negård; Hanne Mari Hamre et al. (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).. (ekstern lenke)

Lederartikkel

• Halfdan Sorbye (2012). Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?. (ekstern lenke)

Konferanseforedrag

• Bengt Glimelius; Halfdan Sørbye; L Balteskard et al. (2005). A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer. (ekstern lenke)
• Pål Joranger; Arild Nesbakken; Geir Hoff et al. (2015). Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer. (ekstern lenke)

Forskningsrapport

• Morten Aaserud; Ivar Sønbø Kristiansen; Aileen Rae Neilson et al. (2007). Helseøkonomisk evaluering av bevacizumab ved metastatisk kolorektalcancer. (ekstern lenke)

Doktorgradsavhandling

• Halfdan Sørbye (1994). Penetration of carcinogens into normal and damaged gastric mucosa. (ekstern lenke)
• Hege Elvebakken; Halfdan Sørbye; Eva Hofsli et al. (2023). High-grade digestive neuroendocrine neoplasms. Impact of genetic alterations and morphologicalcharacteristics on outcome of first-line palliative chemotherapy. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin